10x Genomics (TXG) Common Equity (2018 - 2026)

10x Genomics (TXG) has 9 years of Common Equity data on file, last reported at $814.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 15.2% year-over-year to $814.3 million; the trailing twelve-month figure through Mar 2026 stood at $814.3 million (up 15.2% YoY), and the FY2025 full-year result was $796.3 million, up 12.14% from the prior year.
• Common Equity advanced to $814.3 million in Q1 2026, from $796.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $814.3 million in Q1 2026 to a low of $706.9 million in Q1 2025.
• A 5-year average of $765.0 million and a median of $775.8 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity declined 10.41% in 2024 and gained 15.2% in 2026, its largest moves.
• Tracing TXG's Common Equity over 5 years: stood at $805.7 million in 2022, then decreased by 8.03% to $741.0 million in 2023, then slipped by 4.17% to $710.1 million in 2024, then grew by 12.14% to $796.3 million in 2025, then gained by 2.26% to $814.3 million in 2026.
• Business Quant data shows TXG's Common Equity at $814.3 million in Q1 2026, $796.3 million in Q4 2025, and $785.1 million in Q3 2025.